[go: up one dir, main page]

MX2024002073A - Vectores modificados de orthopoxvirus. - Google Patents

Vectores modificados de orthopoxvirus.

Info

Publication number
MX2024002073A
MX2024002073A MX2024002073A MX2024002073A MX2024002073A MX 2024002073 A MX2024002073 A MX 2024002073A MX 2024002073 A MX2024002073 A MX 2024002073A MX 2024002073 A MX2024002073 A MX 2024002073A MX 2024002073 A MX2024002073 A MX 2024002073A
Authority
MX
Mexico
Prior art keywords
modified orthopoxvirus
vectors
orthopoxvirus vectors
modified
amenable
Prior art date
Application number
MX2024002073A
Other languages
English (en)
Inventor
John C Bell
Boeuf Fabrice Le
Michael S Huh
Matthew Y Tang
Brian Andrew Keller
Adrian Pelin
Caroline J Breitbach
Michael F Burgess
Steven H Bernstein
Original Assignee
Ottawa Hospital Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Hospital Res Inst filed Critical Ottawa Hospital Res Inst
Publication of MX2024002073A publication Critical patent/MX2024002073A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01023—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1) dUTP diphosphatase (3.6.1.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La descripción se refiere a vectores modificados de Orthopoxvirus, así como a métodos para usarlos para el tratamiento de varios cánceres. La descripción proporciona vectores modificados de Orthopoxvirus que exhiben varias actividades terapéuticas beneficiosas, incluidas actividad oncolítica mejorada, propagación de infección, evasión inmunitaria, persistencia del tumor, capacidad para la incorporación de secuencias de ADN exógenas y seguridad. Los virus que se han descubierto también son manejables mediante protocolos de fabricación a gran escala.
MX2024002073A 2018-01-05 2020-07-13 Vectores modificados de orthopoxvirus. MX2024002073A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862614349P 2018-01-05 2018-01-05
US201862784371P 2018-12-21 2018-12-21

Publications (1)

Publication Number Publication Date
MX2024002073A true MX2024002073A (es) 2024-03-04

Family

ID=67144045

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020007010A MX2020007010A (es) 2018-01-05 2019-01-04 Vectores modificados de orthopoxvirus.
MX2024002073A MX2024002073A (es) 2018-01-05 2020-07-13 Vectores modificados de orthopoxvirus.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020007010A MX2020007010A (es) 2018-01-05 2019-01-04 Vectores modificados de orthopoxvirus.

Country Status (12)

Country Link
US (2) US11802292B2 (es)
EP (1) EP3735466A4 (es)
JP (2) JP7312412B2 (es)
KR (1) KR20200121297A (es)
CN (1) CN113039277A (es)
AU (1) AU2019205036A1 (es)
BR (1) BR112020013769A2 (es)
CA (1) CA3122431A1 (es)
IL (1) IL275813A (es)
MX (2) MX2020007010A (es)
SG (1) SG11202006457YA (es)
WO (1) WO2019134048A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210132003A (ko) * 2018-12-21 2021-11-03 오타와 하스피털 리서치 인스티튜트 변형된 오르토폭스 바이러스 벡터
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US20220090133A1 (en) * 2019-03-05 2022-03-24 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
JP7737141B2 (ja) 2019-05-14 2025-09-10 国立大学法人鳥取大学 細胞融合を誘導するワクシニアウイルス及びその利用
US12018289B2 (en) 2019-11-18 2024-06-25 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4014992A1 (en) * 2020-12-21 2022-06-22 Eberhard Karls Universität Tübingen Medizinische Fakultät Modified parapoxvirus having increased immunogenicity
JP2025503721A (ja) * 2022-01-17 2025-02-04 ノイスコム アーゲー がん治療用免疫刺激タンパク質をコードする組換えオルソポックスウイルスベクター
WO2024130212A1 (en) 2022-12-16 2024-06-20 Turnstone Biologics Corp. Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
CN101912421A (zh) 2002-08-12 2010-12-15 杰能斯有限公司 涉及痘病毒和癌的方法及组合物
WO2004034995A2 (en) 2002-10-15 2004-04-29 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods and reagents for inducing immunity
ES2671230T3 (es) 2006-06-20 2018-06-05 Transgene Sa Procedimiento para producir poxvirus y composiciones de poxvirus
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
PE20110223A1 (es) 2008-06-10 2011-05-07 Abbvie Inc DERIVADOS DE PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN, COMO INHIBIDORES DE QUINASA
EP3778897B1 (en) 2013-08-22 2023-12-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Immuno-oncolytic therapies
PT3169341T (pt) 2014-07-16 2019-09-09 Transgene Sa Vírus oncolítico para a expressão de moduladores de pontos de controlo imunitário
CN105255840A (zh) 2015-10-16 2016-01-20 西安医学院 通过去除显性表位b8r重组痘苗病毒的方法及其病毒
AU2017207532A1 (en) 2016-01-11 2018-08-16 Turnstone Limited Partnership Oncolytic virus and checkpoint inhibitor combination therapy
EP3480307B1 (en) * 2016-05-30 2021-06-23 Astellas Pharma Inc. New genetically-modified vaccinia virus
RU2621868C1 (ru) 2016-06-24 2017-06-07 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор"" (ФБУН ГНЦ ВБ "Вектор") Рекомбинантный штамм VACΔ6 вируса осповакцины с нарушенными генами вирулентности C3L, N1L, J2R, A35R, A56R, B8R для получения живой культуральной аттенуированной вакцины против натуральной оспы и других ортопоксвирусных инфекций человека
TW202428301A (zh) 2017-02-28 2024-07-16 法商賽諾菲公司 治療性rna
CA3069821A1 (en) 2017-07-14 2019-01-17 Oncorus, Inc. Encapsulated polynucleotides and methods of use
CN111556757A (zh) 2017-10-31 2020-08-18 西方溶瘤细胞有限公司 用于全身递送的平台溶瘤载体
AU2019205037A1 (en) 2018-01-05 2020-08-20 Ottawa Hospital Research Institute Modified vaccinia vectors
KR20210132003A (ko) 2018-12-21 2021-11-03 오타와 하스피털 리서치 인스티튜트 변형된 오르토폭스 바이러스 벡터

Also Published As

Publication number Publication date
KR20200121297A (ko) 2020-10-23
CN113039277A (zh) 2021-06-25
BR112020013769A2 (pt) 2020-12-01
JP2023126868A (ja) 2023-09-12
MX2020007010A (es) 2020-12-10
CA3122431A1 (en) 2019-07-11
WO2019134048A1 (en) 2019-07-11
US20200392535A1 (en) 2020-12-17
US11802292B2 (en) 2023-10-31
JP2021510082A (ja) 2021-04-15
US20240132913A1 (en) 2024-04-25
IL275813A (en) 2020-08-31
US20240229069A9 (en) 2024-07-11
JP7312412B2 (ja) 2023-07-21
EP3735466A4 (en) 2022-01-12
SG11202006457YA (en) 2020-08-28
EP3735466A1 (en) 2020-11-11
AU2019205036A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
MX2024002073A (es) Vectores modificados de orthopoxvirus.
PH12021551436A1 (en) Modified orthopoxvirus vectors
MX2020007011A (es) Vectores de vaccinia modificados.
MX2021000165A (es) Cepas bacterianas inmunoestimuladoras modificadas y usos de las mismas.
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
PH12019502518A1 (en) Alphavirus neoantigen vectors
CO2017009104A2 (es) Derivados dinucleotidos de purina bis-2’-fluoro-bis-3’-5’-cíclico
MY194058A (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
MX2025014318A (es) Vector de adenovirus de chimpance util para la administracion de neoantigenos
EA201890960A1 (ru) Натуральные киллеры и клетки ilc3 и их применение
PH12017501031A1 (en) Methods and compositions for treating cancer
WO2012149546A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
WO2012142529A3 (en) Clonal strains of attenuated vaccinia viruses and methods of use thereof
MX2018005286A (es) Constructo genetico.
WO2017066706A8 (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
WO2017027757A3 (en) Smallpox vaccine for use in cancer treatment
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
RU2015143513A (ru) Микровезикула и способ ее получения
AU2013358947A8 (en) WT1 vaccine
MX382778B (es) Metodos para tratar cancer pancreatico
PH12017501993A1 (en) Methods of treating epstein-barr-virus-associated lymphoproliferative disorders by t cell therapy
MX2021009554A (es) Produccion de virus en cultivos celulares.
MX2018007307A (es) Conjugados de peptidos y oligonucleotidos.
WO2015170158A8 (en) Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation
WO2014081346A3 (en) Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic sendai virus